套细胞淋巴瘤发病机制的研究进展

Research advances in pathogenesis of mantle cell iymphoma

套细胞淋巴瘤（MCL）是一种侵袭性的非霍奇金淋巴瘤（NHL），该病的经典遗传学标志为t（11；14）（q13；q32）移位和细胞周期蛋白（cyclin）D1过表达，以难治和易复发为临床特征，并且总体预后不良。近年，随着对MCL细胞遗传学及分子发病机制研究的不断深入，靶向药物的开发与应用，使得该病的临床疗效有所提高。本文就近年来MCL发病机制中细胞遗传学、信号通路、转录因子、肿瘤微环境等改变的研究最新进展作一综述，旨在为MCL的早期诊断和靶向治疗提供新的方向。

Mantle cell lymphoma （MCL） is an aggressive subtype of non-Hodgkin lymphoma （NHL）,and genetically characterized by the translocation （11;14）（q13;q32） and the over-expression of cyclin D1. Most MCL patients manifested highly refractory to standard chemotherapy and easy to relapse, associated with poor prognosis. Recently, research advances in the understanding of cytogenetics and molecular pathophysiology of MCL has resulted in an exploitation of specifically targeted drugs, which achieved promisingresults in clinical application. The abnormalities of genetics, signal pathways, transcription factor, and microenvironment of MCL are reviewed in this article, in order to optimize the early diagnosis and provide novel target strategy in MCL.